376 related articles for article (PubMed ID: 15351977)
1. Detection of residual neuroblastoma cells in bone marrow: comparison of flow cytometry with immunocytochemistry.
Swerts K; De Moerloose B; Dhooge C; Brichard B; Benoit Y; Laureys G; Philippé J
Cytometry B Clin Cytom; 2004 Sep; 61(1):9-19. PubMed ID: 15351977
[TBL] [Abstract][Full Text] [Related]
2. Flow cytometric analysis of peripheral blood and bone marrow for tumor cells in patients with neuroblastoma.
Komada Y; Zhang XL; Zhou YW; Inaba H; Deguchi T; Azuma E; Sakurai M
Cancer; 1998 Feb; 82(3):591-9. PubMed ID: 9452279
[TBL] [Abstract][Full Text] [Related]
3. Detection of micrometastasis of neuroblastoma to bone marrow and tumor dissemination to hematopoietic autografts using flow cytometry and reverse transcriptase-polymerase chain reaction.
Tsang KS; Li CK; Tsoi WC; Leung Y; Shing MM; Chik KW; Lee V; Ng MH; Yuen P
Cancer; 2003 Jun; 97(11):2887-97. PubMed ID: 12767104
[TBL] [Abstract][Full Text] [Related]
4. Comparison of immunocytochemistry, real-time quantitative RT-PCR and flow cytometry for detection of minimal residual disease in neuroblastoma.
Ifversen MR; Kågedal B; Christensen LD; Rechnitzer C; Petersen BL; Heilmann C
Int J Oncol; 2005 Jul; 27(1):121-9. PubMed ID: 15942651
[TBL] [Abstract][Full Text] [Related]
5. A new sensitive and specific combination of CD81/CD56/CD45 monoclonal antibodies for detecting circulating neuroblastoma cells in peripheral blood using flow cytometry.
Nagai J; Ishida Y; Koga N; Tanaka Y; Ohnuma K; Toyoda Y; Katoh A; Hayabuchi Y; Kigasawa H
J Pediatr Hematol Oncol; 2000; 22(1):20-6. PubMed ID: 10695817
[TBL] [Abstract][Full Text] [Related]
6. Flow cytometry and fluorescence in situ hybridization to detect residual neuroblastoma cells in bone marrow.
Okcu MF; Wang RY; Bueso-Ramos C; Schober W; Weidner D; Andrassy R; Blakely M; Russell H; Ozkan A; Kuttesch J; Andreeff M; Chan KW; Ater J
Pediatr Blood Cancer; 2005 Nov; 45(6):787-95. PubMed ID: 15929127
[TBL] [Abstract][Full Text] [Related]
7. [Detection of minimal residual disease in children with neuroblastoma].
De Moerloose B; Swerts K
Verh K Acad Geneeskd Belg; 2005; 67(1):33-44. PubMed ID: 15828305
[TBL] [Abstract][Full Text] [Related]
8. Prognostic influence of minimal residual disease detected by flow cytometry and peripheral blood stem cell transplantation by CD34+ selection in childhood advanced neuroblastoma.
Cai JY; Tang YJ; Jiang LM; Pan C; Chen J; Tang JY
Pediatr Blood Cancer; 2007 Dec; 49(7):952-7. PubMed ID: 17514736
[TBL] [Abstract][Full Text] [Related]
9. Detecting CD56+/NB84+/CD45- immunophenotype in the bone marrow of patients with metastatic neuroblastoma using flow cytometry.
Bozzi F; Gambirasio F; Luksch R; Collini P; Brando B; Fossati-Bellani F
Anticancer Res; 2006; 26(5A):3281-7. PubMed ID: 17094441
[TBL] [Abstract][Full Text] [Related]
10. Flow cytometric evaluation of bone marrow plasma cells using CD19, CD45, CD56, CD38, and CD138 and correlation with bone marrow infiltration ratio in multiple myeloma patients.
Kara IO; Sahin B; Paydas S; Cetiner S
Saudi Med J; 2004 Nov; 25(11):1587-92. PubMed ID: 15573184
[TBL] [Abstract][Full Text] [Related]
11. Flow cytometric phenotype of rhabdomyosarcoma bone marrow metastatic cells and its implication in differential diagnosis with neuroblastoma.
Bozzi F; Collini P; Aiello A; Barzanò E; Gambirasio F; Podda M; Meazza C; Ferrari A; Luksch R
Anticancer Res; 2008; 28(3A):1565-9. PubMed ID: 18630512
[TBL] [Abstract][Full Text] [Related]
12. Discrepant flow cytometric expression and function of P-glycoprotein in neuroblastic tumors.
De Moerloose B; Dhooge C; Laureys G; Benoit Y; Demarche M; Devalck C; Plantaz D; Leroy J; Philippé J
Cytometry; 1999 Oct; 37(2):125-32. PubMed ID: 10486524
[TBL] [Abstract][Full Text] [Related]
13. Flow cytometric immunophenotyping test for staging/monitoring neuroblastoma patients.
Warzynski MJ; Graham DM; Axtell RA; Higgins JV; Hammers YA
Cytometry; 2002 Dec; 50(6):298-304. PubMed ID: 12497591
[TBL] [Abstract][Full Text] [Related]
14. PHOX2B is a novel and specific marker for minimal residual disease testing in neuroblastoma.
Stutterheim J; Gerritsen A; Zappeij-Kannegieter L; Kleijn I; Dee R; Hooft L; van Noesel MM; Bierings M; Berthold F; Versteeg R; Caron HN; van der Schoot CE; Tytgat GA
J Clin Oncol; 2008 Nov; 26(33):5443-9. PubMed ID: 18838715
[TBL] [Abstract][Full Text] [Related]
15. Optimization of a flow cytometry-based protocol for detection and phenotypic characterization of multipotent mesenchymal stromal cells from human bone marrow.
Jones EA; English A; Kinsey SE; Straszynski L; Emery P; Ponchel F; McGonagle D
Cytometry B Clin Cytom; 2006 Nov; 70(6):391-9. PubMed ID: 16977637
[TBL] [Abstract][Full Text] [Related]
16. Measuring circulating neuroblastoma cells by quantitative reverse transcriptase-polymerase chain reaction analysis.
Cheung IY; Sahota A; Cheung NK
Cancer; 2004 Nov; 101(10):2303-8. PubMed ID: 15484213
[TBL] [Abstract][Full Text] [Related]
17. Leukemia markers expression of peripheral blood vs bone marrow blasts using flow cytometry.
Rezaei A; Adib M; Mokarian F; Tebianian M; Nassiri R
Med Sci Monit; 2003 Aug; 9(8):CR359-62. PubMed ID: 12942032
[TBL] [Abstract][Full Text] [Related]
18. Quantitation of GD2 synthase mRNA by real-time reverse transcription-polymerase chain reaction: utility in bone marrow purging of neuroblastoma by anti-GD2 antibody 3F8.
Cheung IY; Lo Piccolo MS; Collins N; Kushner BH; Cheung NK
Cancer; 2002 Jun; 94(11):3042-8. PubMed ID: 12115395
[TBL] [Abstract][Full Text] [Related]
19. Classical and atypical neuroblastoma--case reports.
Csáthy L; Kappelmayer J; Szegedi I; Kajtár B; Kiss C; Hevessy Z
Cytometry B Clin Cytom; 2011 Mar; 80(2):134-6. PubMed ID: 21337495
[TBL] [Abstract][Full Text] [Related]
20. Morphologic, flow cytometric and cytogenetic evaluation of bone marrow involvement in B-cell lymphoma.
Gomyo H; Shimoyama M; Minagawa K; Yakushijin K; Urahama N; Okamura A; Yamamoto K; Ito M; Chihara K; Hayashi Y; Matsui T
Haematologica; 2003 Dec; 88(12):1358-65. PubMed ID: 14687988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
